PSA nadir–stratified outcomes of ARPI doublet and docetaxel triplet therapy in metastatic prostate cancer

We identified adults with prostate cancer in the Patient360 Prostate dataset, a U.S.-based de-identified data source derived from electronic health records, linked claims, and mortality data. Patients initiating ARPI doublet (ARPI + androgen deprivation therapy [ADT]), docetaxel doublet (docetaxel + ADT), or triplet (ARPI + ADT + docetaxel) were included. Patient characteristics and treatment regimens were summarized descriptively; overall survival (OS) was estimated using Kaplan–Meier methods.

Patients with mPC were diagnosed between 1990 and 2025. Among patients without privacy-compliant date of birth suppression, median age was 67 years; 79.4% were White and 14.3% Black. ECOG performance status was 0–1 in 86.4%. ARPI doublet was the most common regimen (n = 7,676), followed by triplet (n = 1,389) and docetaxel doublet (n = 1,282; total n = 10,347). Compared with ARPI doublet, patients who received docetaxel-containing regimens had higher prevalence of adverse baseline features, including de novo metastatic disease (triplet 65.7%; docetaxel doublet 68.4% vs ARPI doublet 55.2%), liver metastases (14.8% and 17.9% vs 8.7%), and high-grade disease (Gleason 8–10: 55.5% and 57.2% vs 49.2%). Bone-supportive therapy use was also higher (66.7% and 73.4% vs 56.9%, respectively). A PSA nadir < 0.2 ng/mL was achieved in 42.9%, 29.1% and 30.2% of patients receiving ARPI doublet, docetaxel doublet and triplet, respectively. Median OS from regimen start was 109 months (mo) for ARPI doublet, 79 mo for triplet and 64 mo for docetaxel doublet. When stratified by PSA nadir < 0.2 ng/mL, median OS was substantially longer across all regimens (202, 128 and 104 mo, respectively), whereas among patients not achieving PSA nadir < 0.2 ng/mL, differences between regimens were attenuated (86, 71 and 59 mo, respectively). In multivariable Cox regression, baseline disease characteristics independently associated with worse OS included de novo metastatic disease (HR 3.71), liver metastases (HR 1.87), baseline PSA > 200 ng/mL (HR 1.39), and Gleason score 8–10 (all p < 0.0001).

In the largest cohort to date comparing ARPI doublet and triplet therapy, ARPI doublet was the most common regimen and was associated with more favorable outcomes, even after multivariable adjustment. Non-achievement of PSA nadir identifies a population with poorer survival in whom docetaxel triplet therapy may be associated with improved outcomes, supporting the rationale underlying the TRIPLE-SWITCH (SWOG/CCTG-PR26) clinical trial.